<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidemiology, pathology, and molecular genetics of Ewing sarcoma
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidemiology, pathology, and molecular genetics of Ewing sarcoma
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidemiology, pathology, and molecular genetics of Ewing sarcoma
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Francis J Hornicek, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Armita Bahrami, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth H Baldini, MD, MPH, FASTRO
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alberto S Pappo, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert Maki, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Raphael E Pollock, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melinda Yushak, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 07, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ewing sarcoma (ES) is a rare malignancy that most often presents as an undifferentiated primary bone tumor; less commonly, it arises in soft tissue (extraosseous ES [EES]).
        </p>
        <p>
         The epidemiology, pathology, and molecular genetics of ES are presented here. The clinical features, diagnosis, and treatment of ES, diagnostic and biopsy techniques for bone tumors, principles of surgical management for bone sarcomas, and central nervous system embryonal tumors are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7744.html" rel="external">
          "Clinical presentation, staging, and prognostic factors of Ewing sarcoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7740.html" rel="external">
          "Treatment of Ewing sarcoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7748.html" rel="external">
          "Radiation therapy for Ewing sarcoma family of tumors"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7741.html" rel="external">
          "Bone tumors: Diagnosis and biopsy techniques"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7739.html" rel="external">
          "Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5202.html" rel="external">
          "Uncommon brain tumors", section on 'CNS embryonal tumor NEC/NOS'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1454206717">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         We use the term Ewing sarcoma (ES), based on nomenclature from the World Health Organization (WHO) pathology classification system. Several terms previously used to describe ES include the Ewing sarcoma family of tumors (EFT), peripheral primitive neuroectodermal tumor (PNET), peripheral neuroepithelioma, and small cell tumors of the chest wall (previously known as Askin tumor) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         ES was originally described as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In 1918, Stout described a tumor of the ulnar nerve with the gross features of a sarcoma but composed of small round cells focally arranged as rosettes; this entity was historically designated as neuroepithelioma, and then peripheral primitive neuroectodermal tumor [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ES was described by James Ewing in 1921 as an undifferentiated tumor involving the diaphysis of long bones that, in contrast to osteosarcoma, was radiation sensitive. Although most often a primary bone tumor, ES was also reported to arise in soft tissue (extraosseous ES [EES]) [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         However, it has become known that these entities comprise the same spectrum of neoplastic diseases known as ES, which also includes malignant small cell tumors of the chest wall (historically called Askin tumor) [
         <a href="#rid5">
          5
         </a>
         ] and "atypical" ES [
         <a href="#rid1">
          1,6
         </a>
         ]. These tumors likely derive from a common cell of origin because of their similar histologic and immunohistochemical characteristics and their shared nonrandom chromosomal translocations [
         <a href="#rid7">
          7-14
         </a>
         ]. The histogenesis of the cell of origin is discussed below. (See
         <a class="local">
          'Histogenesis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary bone tumors are responsible for 6 percent of all childhood cancers [
         <a href="#rid15">
          15
         </a>
         ]. Although rare, ES represents the second most common primary bone malignancy  (
         <a class="graphic graphic_table graphicRef81481" href="/z/d/graphic/81481.html" rel="external">
          table 1
         </a>
         ) affecting children and adolescents, after osteosarcoma [
         <a href="#rid16">
          16,17
         </a>
         ]. Despite this, ES is responsible for only 3.5 percent of cancers in American children 10 to 14 years old and for 2.3 percent of those arising among 15 to 19 year olds. A similar incidence (2.8 percent of all tumors in children aged 15 to 19 years old) is described in adolescents in England [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         In the United States, 650 to 700 children and adolescents younger than 20 years old are diagnosed with bone tumors every year, of which only 200 are ES and the remainder osteosarcomas [
         <a href="#rid19">
          19
         </a>
         ]. The peak incidence is between 10 to 15 years of age. However, 30 percent of cases arise in children under the age of 10, and another 30 percent are in adults over the age of 20 [
         <a href="#rid20">
          20,21
         </a>
         ]. As with many pediatric tumors, there is a slight male predominance.
        </p>
        <p>
         Racial and ethnic factors are of epidemiologic importance. For unclear reasons, ES affects mainly White populations and are extremely uncommon in Black populations (both in the United States and Africa) and in populations from Asia (eg, Japan, Korea, China, Hong Kong, and Thailand).  (
         <a class="graphic graphic_figure graphicRef81715" href="/z/d/graphic/81715.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid21">
          21-24
         </a>
         ]. The reason for this striking ethnic distribution is not known. However, interethnic differences exist for certain alleles of the ES gene (the
         <em>
          EWSR1
         </em>
         gene, MIM#133450), which is consistently disrupted in these tumors [
         <a href="#rid25">
          25
         </a>
         ] (see
         <a class="local">
          'EWSR1 translocations'
         </a>
         below). Furthermore, genome-wide association studies have raised the possibility that genetic susceptibility factors may contribute to the observed geographical/ethnic differences in ES incidence [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         ES has not been consistently associated with specific familial or congenital syndromes [
         <a href="#rid27">
          27,28
         </a>
         ]. However, at least one series reports an excess of congenital mesenchymal defects in affected patients [
         <a href="#rid29">
          29
         </a>
         ], and another suggests an increase in neuroectodermal tumors and stomach cancer in the families of patients with ES [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         Furthermore, a minority of cases may be associated with an inherited cancer predisposition. In a study that used next-generation sequencing to determine the contribution of germline predisposition mutations in 1120 children with cancer, mutations that were deemed to be pathogenic or probably pathogenic were identified in 5 out of 46 (11 percent) patients with ES [
         <a href="#rid31">
          31
         </a>
         ]. Three of the germline mutations were in
         <em>
          TP53,
         </em>
         the gene associated with Li-Fraumeni syndrome, two were in the
         <em>
          RET
         </em>
         gene, which is associated with multiple endocrine neoplasia type 2 (MEN2), and one was in the
         <em>
          PMS2
         </em>
         gene, which is involved in DNA mismatch repair. Importantly, family history did not predict the presence of an underlying predisposition syndrome in most patients. Despite these data, a causative/pathogenic role for these inherited germline mutations in the development of ES has not been demonstrated. (See
         <a class="medical medical_review" href="/z/d/html/14255.html" rel="external">
          "Li-Fraumeni syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7869.html" rel="external">
          "Classification and genetics of multiple endocrine neoplasia type 2"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7870.html" rel="external">
          "Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2"
         </a>
         .)
        </p>
        <p>
         Specific environmental exposures have
         <strong>
          not
         </strong>
         been identified as risk factors [
         <a href="#rid28">
          28,32
         </a>
         ]. ES develops rarely after treatment of a primary cancer during childhood, but most cases do not appear to be related to radiation therapy [
         <a href="#rid33">
          33,34
         </a>
         ]. An association has been suggested between a parental occupation of farming (particularly if the mother farmed) and the development of ES [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         ES may be more common in children who have hernias [
         <a href="#rid35">
          35-39
         </a>
         ]. A meta-analysis of three case-control studies (totaling 357 patients with ES and 745 controls [
         <a href="#rid37">
          37-39
         </a>
         ]) showed that affected children were more likely to have had a hernia in childhood (odds ratio 3.2, 95% CI 1.9-5.7) [
         <a href="#rid35">
          35
         </a>
         ]. The association was strongest for umbilical hernias. The mechanism underlying a possible association between hernias and ES is unclear.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          HISTOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The histogenic origin of ES has been debated. Both neuroectodermal cells and mesenchymal progenitor cells have been suggested as possible cells or origin. Additional data will be required to draw a final conclusion as to the cell of origin in ES. (See
         <a class="local">
          'EWSR1 translocations'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuroectodermal cells
         </strong>
         – A neuroectodermal origin had been proposed based upon variable expression of neuronal immunohistochemical markers, cytogenetic, and ultrastructural features, as well as the ability of ES cell lines to differentiate along neural pathways in vitro [
         <a href="#rid11">
          11-13,40,41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mesenchymal progenitor cells
         </strong>
         – An alternative theory supported by other data suggests that ES arises from mesenchymal progenitor or mesenchymal stem cells (MSC) [
         <a href="#rid14">
          14,42
         </a>
         ]. MSCs isolated from bone marrow can differentiate into osteogenic, chondrogenic, or adipogenic lineages. Expression of the ES-specific oncoprotein EWS-FLI blocks MSC differentiation [
         <a href="#rid43">
          43
         </a>
         ], while removal of EWS-FLI from patient-derived ES cell lines allows the cells to gain the ability to differentiate into multiple lineages and adapt a gene expression profile that resembles that of MSCs [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          HISTOLOGIC FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The morphologic appearance of classic ES is that of a primitive, undifferentiated neoplasm. On hematoxylin and eosin-stained sections, there are sheets of uniform, small, round, blue cells with a high nuclear cytoplasmic ratio, hyperchromatic nuclei with finely dispersed chromatin, and scant cytoplasm with variable cytoplasmic clearing due to the presence of abundant glycogen  (
         <a class="graphic graphic_picture graphicRef63471" href="/z/d/graphic/63471.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid44">
          44
         </a>
         ]. There is usually extensive necrosis, with preservation of viable tumor around blood vessels. Some tumors historically referred to as peripheral primitive neuroectodermal tumor (PNET) exhibit rosette-like structures and a more prominent neuroectodermal differentiation. Mitotic figures are typically infrequent, and aneuploidy is uncommon on flow cytometry studies [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         "Atypical" ES represents a histologic variant of ES; they are described as having larger cells, greater nuclear pleomorphism, prominent nucleoli, and a higher mitotic rate.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Morphologically, the appearance of ES overlaps that of other small round blue cell tumors (SRBCTs) involving bone and soft tissue, including lymphoma, small cell osteosarcoma, mesenchymal chondrosarcoma, undifferentiated neuroblastoma, poorly differentiated synovial sarcoma, desmoplastic small round cell tumors, rhabdomyosarcoma, and sarcomas with
         <em>
          CIC-DUX4
         </em>
         or
         <em>
          BCOR
         </em>
         genetic alterations. As a group, these tumors can pose difficult diagnostic problems when examined by light microscopy alone. There is little in the routine histologic appearance of ES to relate it to a component of normal bone or other tissue from which it might have arisen. Even the determination of bone versus soft tissue origin can be challenging because ES involving bone often have an extensive soft tissue component, while extraosseous tumors may invade bone secondarily.
        </p>
        <p>
         Although ES can exhibit a variable degree of neural differentiation, this is usually subtle and often only detected by immunohistochemical staining for markers of neural differentiation or by ultrastructural examination. Although no routinely used histochemical or immunohistochemical stain can positively distinguish ES from other undifferentiated small round cell tumors of childhood, the vast majority of ES express high levels of a cell surface glycoprotein (designated CD99, MIC2 surface antigen or p30/32MIC2) that is encoded by the
         <em>
          CD99
         </em>
         (
         <em>
          MIC2X
         </em>
         ) gene [
         <a href="#rid7">
          7,46
         </a>
         ]. The finding of membrane-localized
         <em>
          MIC2
         </em>
         expression is a sensitive diagnostic marker for the ES; however, it lacks specificity since other tumors (eg, rhabdomyosarcoma, which is often in the differential diagnosis) and some normal tissues can also be immunoreactive with anti-MIC2 antibodies [
         <a href="#rid47">
          47
         </a>
         ]. Another potential immunohistochemical marker for ES is NKX2.2, the protein product of the
         <em>
          NKX2-2
         </em>
         gene [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         <em>
          EWSR1
         </em>
         -fusion-negative SRBCTs have been further characterized by several novel translocations. These include SRBCTs with CIC-DUX4 gene fusions and those with
         <em>
          BCOR
         </em>
         fusions. These tumors, some of which in the past were called "atypical" ES, are better identified as Ewing-like sarcoma, an entity different from ES. SRBCTs with CIC-DUX4 gene fusions result from either a t(4;19) or t(10;19) translocation and is the most common genetic abnormality detected in
         <em>
          EWSR1
         </em>
         fusion-negative SRBCTs. These are associated with an aggressive clinical course [
         <a href="#rid49">
          49
         </a>
         ]. SRBCTs with
         <em>
          BCOR
         </em>
         fusions tend to occur in males, with a predilection for older children and adolescents as the most commonly affected population [
         <a href="#rid50">
          50
         </a>
         ]. They appear to be more chemosensitive and have a more favorable clinical outcome than the
         <em>
          CIC
         </em>
         -rearranged sarcomas [
         <a href="#rid51">
          51
         </a>
         ]. Patients with these novel translocations should also be referred for evaluation at sarcoma centers of excellence.
        </p>
        <p>
         Cytogenetic or molecular genetic studies looking for particular chromosomal translocations and/or their fusion transcripts are usually required to secure the diagnosis. (See
         <a class="local">
          'Molecular diagnostics'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          MOLECULAR GENETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Remarkable progress has been made in defining and classifying bone and soft tissue tumors on the basis of characteristic chromosomal abnormalities  (
         <a class="graphic graphic_table graphicRef64666" href="/z/d/graphic/64666.html" rel="external">
          table 2
         </a>
         ). Because of their unique shared chromosomal translocations, ES has become a model system for nonmorphologic approaches to diagnosis and subclassification using both cytogenetic and molecular techniques. These translocations interrupt specific genes and recombine them to create novel fusion genes, whose products are tumor specific and present in virtually all cases of an individual tumor category. Thus, their characterization not only yields profound insights into tumor biology, but also holds great promise for diagnostic and therapeutic approaches. (See
         <a class="medical medical_review" href="/z/d/html/7737.html" rel="external">
          "Pathogenetic factors in soft tissue and bone sarcomas", section on 'Chromosomal translocations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          <i>
           EWSR1
          </i>
          translocations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The unique shared pattern of nonrandom chromosomal translocations in ES provides one of the most compelling arguments for a common cellular origin. Virtually all cases express one of several different reciprocal translocations, most of which involve breakpoints that are clustered within a single gene locus, designated the
         <em>
          EWSR1
         </em>
         gene on chromosome 22q12  (
         <a class="graphic graphic_table graphicRef64666" href="/z/d/graphic/64666.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid8">
          8,9,44,52-55
         </a>
         ].
        </p>
        <p>
         The
         <em>
          EWSR1
         </em>
         gene normally encodes a widely expressed protein, the EWS protein, whose amino terminal domain shares some homology with eukaryotic RNA polymerase II and whose carboxy terminus (which is replaced by tumor-specific translocations) contains an RNA recognition motif. The EWS protein is a member of a family of highly conserved RNA binding proteins that are believed to mediate interaction with RNA or single-stranded DNA [
         <a href="#rid56">
          56,57
         </a>
         ].
        </p>
        <p>
         In 85 to 90 percent of cases of ES, a recurrent chromosomal translocation, t(11;22)(q24;q12), fuses the 5' portion of the
         <em>
          EWSR1
         </em>
         gene on chromosome 22 to the 3' portion of the
         <em>
          FLI1
         </em>
         gene on chromosome 11 [
         <a href="#rid52">
          52,53
         </a>
         ]. This can be detected using fluorescence in situ hybridization (FISH)  (
         <a class="graphic graphic_diagnosticimage graphicRef62731" href="/z/d/graphic/62731.html" rel="external">
          image 1
         </a>
         ).
        </p>
        <p>
         <em>
          FLI1
         </em>
         encodes the FLI protein, a member of the ETS family of transcription factors, and is involved in the control of cellular proliferation, development, and tumorigenesis [
         <a href="#rid58">
          58
         </a>
         ]. Members of the ETS family are defined by the presence of a highly conserved 85-amino acid domain, termed the erythroblastosis virus-transforming sequence (ETS) domain, which mediates specific binding to purine-rich DNA sequences [
         <a href="#rid59">
          59
         </a>
         ]. As a result of the t(11;22), the EWS-FLI fusion protein is expressed. EWS-FLI binds DNA via its FLI-derived ETS domain and regulates gene expression through the EWS portion of the fusion.
        </p>
        <p>
         In ES that lack the
         <em>
          EWSR1-FLI1
         </em>
         translocation, analogous translocations fuse the
         <em>
          EWSR1
         </em>
         gene to other genes of the ETS family (ie,
         <em>
          ERG
         </em>
         ,
         <em>
          ETV1
         </em>
         ,
         <em>
          ETV4
         </em>
         , or
         <em>
          FEV
         </em>
         ) that have structural homology to
         <em>
          FLI1
         </em>
         , forming t(21;22)(q22;q12), t(7;22)(p22;q12), t(17;22)(q12;q12), or t(2;22)(q35;q12) translocations, respectively [
         <a href="#rid60">
          60-63
         </a>
         ]. The
         <em>
          EWSR1-ERG
         </em>
         translocation [t(21;22) (q22;q12)] is present in 5 to 10 percent of ES, while the others are less common [
         <a href="#rid63">
          63-66
         </a>
         ].
        </p>
        <p>
         In addition to
         <em>
          EWSR1
         </em>
         -based translocations, rare cases of ES are associated with translocations involving a related gene,
         <em>
          FUS
         </em>
         (also called
         <em>
          TLS
         </em>
         ) [
         <a href="#rid67">
          67,68
         </a>
         ]. Tumors exhibiting t(16;21)(p11;q24) or t(2;16)(q35;p11) translocations express FUS-ERG or FUS-FEV fusions, respectively. Because EWS and FUS proteins are highly similar, it is believed that FUS-based fusion proteins function similarly to EWS-based fusions. It is important to note that tumors with these translocations can be a source of diagnostic confusion. (See
         <a class="local">
          'Molecular diagnostics'
         </a>
         below.)
        </p>
        <p>
         Ultimately, specific translocations are important diagnostic features of ES, and the protein products of the fusion genes are believed to play an important role in tumor development and biology. A growing body of evidence suggests that these proteins function as transcriptional regulators, although their transcriptional targets are just beginning to be identified. (See
         <a class="local">
          'Molecular pathogenesis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          <i>
           EWSR1
          </i>
          translocations in other soft tissue tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although translocations involving the
         <em>
          EWSR1
         </em>
         and
         <em>
          ETS
         </em>
         families of genes are specific for ES, translocations that involve fusion of the
         <em>
          EWSR1
         </em>
         gene to other genes have been observed in many other tumors (eg, clear cell sarcoma/malignant melanoma of soft parts, desmoplastic small round cell tumor [
         <a href="#rid69">
          69-71
         </a>
         ]). The structure of these resultant fusion genes is analogous to that of
         <em>
          EWSR1-FLI1
         </em>
         (ie, all result in the fusion of the 5' portions of the
         <em>
          EWSR1
         </em>
         gene or an
         <em>
          EWSR1
         </em>
         -like gene [eg, the
         <em>
          FUS
         </em>
         gene] to 3' portions of genes encoding transcription factors). The resulting chimeric proteins presumably have a similar function to the EWS-FLI fusion protein, and it is thought that disruption of transcriptional control contributes to their transforming potential [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="local">
          'Molecular pathogenesis'
         </a>
         below.)
        </p>
        <p>
         With few exceptions, a clinicopathologically distinct tumor entity has been consistently associated with each specific translocation involving a unique class of transcription factors. This tumor specificity is most likely related to cell-specific influences on DNA recombination, target genes of the fusion transcription factor involved, chimeric gene expression, and intrinsic proteins that are necessary to complement the action of the chimeric protein.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Other genetic changes
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to the characteristic reciprocal translocations described above, other numerical and structural chromosomal aberrations are occasionally found in ES. These include a gain of chromosomes 1q, 2, 8, and 12, losses of 9p and 16q, and the nonreciprocal translocation t(1;16)(q12;q11.2) [
         <a href="#rid72">
          72-74
         </a>
         ]. In addition, alterations in known tumor suppressor genes have been identified in some cases. As an example, homozygous deletion of the
         <em>
          CDKN2A
         </em>
         gene has been described in 12 to 30 percent of cases, and
         <em>
          TP53
         </em>
         mutations are detected in 5 to 20 percent [
         <a href="#rid44">
          44,75-77
         </a>
         ]. Finally, loss-of-function mutations in
         <em>
          STAG2
         </em>
         have also been identified in more than 15 percent of cases [
         <a href="#rid78">
          78-81
         </a>
         ].
        </p>
        <p>
         The biologic implications of these findings are incompletely understood and are somewhat controversial, with some studies suggesting an adverse prognostic impact of some of these alterations [
         <a href="#rid77">
          77-80
         </a>
         ], while others have failed to confirm such a correlation [
         <a href="#rid82">
          82
         </a>
         ]. More recently, loss-of-function alterations in
         <em>
          STAG2
         </em>
         have been identified and have also been suggested to be predictive of poor outcome in patients with ES, particularly when concurrent with
         <em>
          TP53
         </em>
         mutations [
         <a href="#rid78">
          78
         </a>
         ]. At this time, however, these data are preliminary, and they require validation before any molecular test can be used to change clinical decision-making.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Molecular pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         ES-associated translocations result in the production of chimeric proteins that contain the amino-terminal domain of the normal EWS protein fused to the nucleic acid-binding domain of the transcription factor translocation partner. Because of their ubiquitous presence in ES, they are thought to be intimately connected to the biology of these tumors.
        </p>
        <p>
         The available data suggest two possible mechanisms by which these unique chimeric proteins may contribute to neoplastic transformation and/or cell growth:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chimeric proteins such as EWS-FLI may influence transcription of some of the same genes that are normally regulated by native FLI, but because the chimeric molecule is expressed in either a different temporal or quantitative manner, the downstream targets are deregulated, leading to uncontrolled cellular growth.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         EWS-FLI may affect target genes that are different from those regulated by the native FLI or EWS proteins. This would explain why the chimeric gene product (EWS-FLI) has transforming properties that are not shared by either the EWS or FLI wild-type counterparts [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Some chimeric fusion proteins can act as transcriptional activators, deregulating many genes associated with cell signaling, proliferation, apoptosis, tissue invasion, and metastasis [
         <a href="#rid44">
          44,83-90
         </a>
         ]. It is likely that this ability to regulate transcriptional activity is associated with their oncogenic potential. EWS-FLI and other chimeric fusion proteins are all capable of transforming cell lines equally well. As an example, expression of either the EWS-FLI or EWS-ERG cDNAs can transform mouse NIH3T3 fibroblasts so that they acquire tumor-like properties (eg, growth in soft agar or in immunodeficient mice) [
         <a href="#rid83">
          83,91
         </a>
         ]. Notably, EWS-FLI can only transform cells in which insulin-like growth factor signaling is intact, and thus, there is a potential role for insulin-like growth factor 1 receptor (IGF1R) inhibitors in the treatment of ES [
         <a href="#rid92">
          92-94
         </a>
         ].
        </p>
        <p>
         The protein products of the fused genes are also important for maintaining the growth characteristics of ES cell lines, and emerging data suggest the potential for molecularly targeted therapy [
         <a href="#rid95">
          95
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Introduction of EWS-FLI RNA antisense molecules or short-interfering or short-hairpin RNAs (such as RNAi that mediate RNA-interference) into ES cells decreases the expression of the EWS-FLI fusion protein and results in growth inhibition and/or loss of oncogenic potential, both in vitro and in vivo [
         <a href="#rid96">
          96-100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Likewise, inhibition of the interaction between EWS-FLI and its cellular binding partner RNA helicase A (RHA) by a small peptide or small molecule inhibitor reduces the growth of ES orthotopic xenografts [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Truncated ETS domain-binding molecules can act as competitive inhibitors and have a dominant negative effect on cell growth [
         <a href="#rid102">
          102
         </a>
         ]. p21(WAF1/CIP1), which is important in cell cycle regulation, might be one of the direct targets of EWS-FLI, suggesting that this molecule could serve as a target for a molecularly based therapy for ES [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Because EWS-FLI and related fusions are thought to function primarily as transcriptional regulators, a number of studies have sought to define the genes that are regulated by the fusion proteins [
         <a href="#rid98">
          98-100,103,104
         </a>
         ]. Some of the EWS-FLI-regulated genes are involved in the oncogenic phenotype of ES model systems (eg,
         <em>
          IGFBP3
         </em>
         ,
         <em>
          CAV1
         </em>
         ,
         <em>
          NKX2.2
         </em>
         ,
         <em>
          NR0B1
         </em>
         ,
         <em>
          GSTM4
         </em>
         , and others) [
         <a href="#rid85">
          85,98-100,105,106
         </a>
         ]. While many of the details are still being worked out, some of these gene targets and associated pathways may prove to be future targets for molecularly targeted therapy.
        </p>
        <p>
         Another mechanism whereby EWS-FLI may exert a tumorigenic effect is via deregulation of programmed cell death (apoptosis). Cancer is believed, in part, to represent an imbalance between cell growth and cell death. Expression of
         <em>
          EWS-FLI1
         </em>
         or
         <em>
          EWS-ERG
         </em>
         in NIH3T3 cells inhibits the apoptosis that would normally occur with serum deprivation or calcium ionophore treatment [
         <a href="#rid107">
          107
         </a>
         ], while antisense inhibition of EWS-FLI increases susceptibility to chemotherapy-induced apoptosis in ES cell lines. Similarly, reduced expression of EWS-FLI using RNAi-based approaches also resulted in increased apoptosis [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
         EWS-ETS fusion proteins also activate human telomerase activity in Ewing tumors through upregulation of the telomerase reverse transcriptase gene expression, probably by acting as a transcriptional coactivator [
         <a href="#rid108">
          108
         </a>
         ]. Telomerase is a ribonucleoprotein enzyme that compensates for telomere shortening during cell division by synthesizing telomeric DNA, thereby maintaining telomere length. In normal somatic cells, telomerase activity is usually undetectable, with the exception of some cell types, such as hematopoietic cells, hair follicles, intestinal crypt cells, and basal cells of the epidermis. Upregulated telomerase activity in cancer cells correlates with the stabilization of telomere length and cellular immortalization (ie, the ability of the cells to divide indefinitely). This raises the possibility of therapeutic approaches using telomerase inhibitors.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Molecular diagnostics
         </span>
         <span class="headingEndMark">
          —
         </span>
         The translocations that characterize ES are exquisitely sensitive and specific tumor markers that have rapidly become the standard for confirming the diagnosis, particularly for cases in which morphology is inconclusive [
         <a href="#rid8">
          8,109
         </a>
         ]. Standard cytogenetic analysis can reveal a wide variety of chromosomal alterations, but technical constraints and variant translocations may complicate the interpretation, and results are often obtained too late to influence therapy. Molecular assays are more attractive because of the small amount of tissue required, rapid results, and higher sensitivity than traditional cytogenetics.
        </p>
        <p>
         Both the fusion genes and their hybrid transcripts can be identified in tumor cells using molecular genetic approaches. Two techniques are in use, FISH and reverse transcriptase polymerase chain reaction (RT-PCR), and both are more rapid than cytogenetic analysis [
         <a href="#rid110">
          110-113
         </a>
         ]. In particular, RT-PCR to detect the presence of fusion transcripts in tumor cells has become a mainstay in molecular diagnosis of ES. It is extremely sensitive and specific, and allows detection of very low levels of tumor cells, even among large numbers of normal cells (eg, peripheral blood and bone marrow), providing an extremely robust method for molecular staging and monitoring treatment response.
        </p>
        <p>
         In addition to providing diagnostic support for challenging cases, the identification of specific types of transcripts was at one time thought to have prognostic significance [
         <a href="#rid72">
          72,114,115
         </a>
         ]. As an example, in one report, the presence of type 1 EWS-FLI transcripts (
         <em>
          EWSR1
         </em>
         exon 7 fused with
         <em>
          FLI1
         </em>
         exon 6) was associated with a threefold reduction in the risk of developing metastatic disease as compared with non-type 1 transcripts [
         <a href="#rid114">
          114
         </a>
         ]. However, more recent independent studies from both the United States and Europe do not support the prognostic value of translocation type [
         <a href="#rid116">
          116,117
         </a>
         ]. It appears that current intensive treatment protocols may have eliminated this apparent difference in prognosis. (See
         <a class="medical medical_review" href="/z/d/html/7744.html" rel="external">
          "Clinical presentation, staging, and prognostic factors of Ewing sarcoma", section on 'Prognostic factors'
         </a>
         .)
        </p>
        <p>
         While molecular tests for ES-associated translocations are important and often useful adjuncts in the diagnostic workup, in most cases, molecular pathology laboratories do not test for all of the "alternate" translocations (such as those that encode EWSR1-ETV1, EWSR1-ETV4, EWSR1-FEV, FUS-ERG, and FUS-FEV). Thus, a "negative" FISH or RT-PCR result does not necessarily rule out the diagnosis of ES. Physicians are strongly advised to consult with their molecular diagnostic laboratory to understand exactly what tests are performed and the sensitivity and specificity of those tests for ES. Ultimately, the diagnosis of ES is based upon a combination of histopathology, immunohistochemical stains, and molecular diagnostics that are interpreted in the context of the patient's clinical presentation.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Molecular staging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disease stage as determined by standard imaging modalities constitutes the most powerful predictor of prognosis for patients with ES. However, some patients considered to have localized disease have an unfavorable outcome, even with multimodality therapy, and this may be related to the persistence of minimal metastatic disease that is not detected by traditional methods. (See
         <a class="medical medical_review" href="/z/d/html/7744.html" rel="external">
          "Clinical presentation, staging, and prognostic factors of Ewing sarcoma", section on 'Prognostic factors'
         </a>
         .)
        </p>
        <p>
         Minimal disease (ie, circulating ES cells) can be detected in peripheral blood and bone marrow using PCR-based methods in up to 30 percent of patients with apparently localized disease and in approximately 50 percent of those with advanced or relapsed disease [
         <a href="#rid118">
          118-122
         </a>
         ]. However, the prognostic significance of this finding, particularly in patients with localized disease, is controversial [
         <a href="#rid119">
          119,121,122
         </a>
         ], and the ultimate contribution of this finding to patient management is unclear [
         <a href="#rid121">
          121,122
         </a>
         ]. Further prospective studies using molecular methods to detect the presence of minimal residual disease are needed in order to assess its impact on outcome.
        </p>
        <p class="headingAnchor" id="H4030205122">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119797.html" rel="external">
          "Society guideline links: Soft tissue sarcoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H113087253">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/83150.html" rel="external">
          "Patient education: Bone cancer (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H684655">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Although rare, Ewing sarcoma (ES) represents the second most common primary bone malignancy  (
         <a class="graphic graphic_table graphicRef81481" href="/z/d/graphic/81481.html" rel="external">
          table 1
         </a>
         ) affecting children and adolescents. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – ES has not been consistently associated with any familial or congenital syndromes, and specific environmental exposures have not been identified as risk factors. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Histologic features
         </strong>
         <strong>
          and differential diagnosis
         </strong>
         – The morphologic appearance of classic ES is that of a primitive, undifferentiated neoplasm  (
         <a class="graphic graphic_picture graphicRef63471" href="/z/d/graphic/63471.html" rel="external">
          picture 1
         </a>
         ), which overlaps with that of other small, round, blue cell tumors (SBCTs) involving bone and soft tissue. Such tumors include lymphoma, small cell osteosarcoma, mesenchymal chondrosarcoma, undifferentiated neuroblastoma, poorly differentiated synovial sarcoma, desmoplastic small round cell tumors, and rhabdomyosarcoma, and sarcomas with
         <em>
          CIC-DUX4
         </em>
         or
         <em>
          BCOR
         </em>
         genetic alterations. (See
         <a class="local">
          'Histologic features'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Molecular diagnostics
         </strong>
         – ES often poses difficult diagnostic problems when examined by light microscopy alone. Cytogenetic or molecular genetic studies looking for particular chromosomal translocations and/or their fusion transcripts are usually required to secure the diagnosis  (
         <a class="graphic graphic_table graphicRef64666" href="/z/d/graphic/64666.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Molecular diagnostics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Characteristic molecular translocations
         </strong>
         – Virtually all cases of ES express one of several different reciprocal translocations. Most involve breakpoints that are clustered within a single gene locus, designated the
         <em>
          EWSR1
         </em>
         gene on chromosome 22q12. (See
         <a class="local">
          'EWSR1 translocations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Molecular pathogenesis
         </strong>
         – ES-associated translocations result in the production of chimeric proteins that contain the amino-terminal domain of the normal EWS protein fused to the nucleic acid-binding domain of the transcription factor translocation partner. Because of their ubiquitous presence in ES, these chimeric proteins are thought to be intimately connected to the biology of these tumors. (See
         <a class="local">
          'Molecular pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H994687273">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Henry J Mankin, MD; Stephen L Lessnick, MD, PhD; and Thomas F DeLaney, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Grier HE. The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am 1997; 44:991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaffe R, Santamaria M, Yunis EJ, et al. The neuroectodermal tumor of bone. Am J Surg Pathol 1984; 8:885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angervall L, Enzinger FM. Extraskeletal neoplasm resembling Ewing's sarcoma. Cancer 1975; 36:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maki RG, Grohar PJ, Antonescu CR. Ewing sarcoma and related FET family translocation-associated round cell tumors: A century of clinical and scientific progress. Genes Chromosomes Cancer 2022; 61:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Askin FB, Rosai J, Sibley RK, et al. Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer 1979; 43:2438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Llombart-Bosch A, Lacombe MJ, Contesso G, Peydro-Olaya A. Small round blue cell sarcoma of bone mimicking atypical Ewing's sarcoma with neuroectodermal features. An analysis of five cases with immunohistochemical and electron microscopic support. Cancer 1987; 60:1570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambros IM, Ambros PF, Strehl S, et al. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 1991; 67:1886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denny CT. Gene rearrangements in Ewing's sarcoma. Cancer Invest 1996; 14:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Llombart-Bosch A, Carda C, Peydro-Olaya A, et al. Soft tissue Ewing's sarcoma. Characterization in established cultures and xenografts with evidence of a neuroectodermic phenotype. Cancer 1990; 66:2589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thiele CJ. Biology of pediatric peripheral neuroectodermal tumors. Cancer Metastasis Rev 1991; 10:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Regan S, Diebler MF, Meunier FM, Vyas S. A Ewing's sarcoma cell line showing some, but not all, of the traits of a cholinergic neuron. J Neurochem 1995; 64:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawlor ER, Lim JF, Tao W, et al. The Ewing tumor family of peripheral primitive neuroectodermal tumors expresses human gastrin-releasing peptide. Cancer Res 1998; 58:2469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tirode F, Laud-Duval K, Prieur A, et al. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007; 11:421.
          </a>
         </li>
         <li class="breakAll">
          Cancer Incidence and Survivalamong Children and Adolescents:
United States SEER Program 1975-1995 http://seer.cancer.gov/publications/childhood/introduction.pdf (Accessed on May 31, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006; 42:2124.
          </a>
         </li>
         <li class="breakAll">
          Bleyer A, O’Leary M, Barr R, Ries LAG. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. NIH Pub. No. 06-5767, National Cancer Institute, Bethesda, MD 2006.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birch JM, Alston RD, Kelsey AM, et al. Classification and incidence of cancers in adolescents and young adults in England 1979-1997. Br J Cancer 2002; 87:1267.
          </a>
         </li>
         <li class="breakAll">
          Gurney JG, Swensen AR, Bulterys M. Malignant Bone Tumors. In: Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, Ries LA, Smith MA, Gurney JG, et al (Eds), NCI, SEER Program, Bethesda, MD 1999.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glass AG, Fraumeni JF Jr. Epidemiology of bone cancer in children. J Natl Cancer Inst 1970; 44:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller RW. Contrasting epidemiology of childhood osteosarcoma, Ewing's tumor, and rhabdomyosarcoma. Natl Cancer Inst Monogr 1981; :9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fraumeni JF Jr, Glass AG. Rarity of Ewing's sarcoma among U.S. Negro children. Lancet 1970; 1:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parkin DM, Stiller CA, Nectoux J. International variations in the incidence of childhood bone tumours. Int J Cancer 1993; 53:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jawad MU, Cheung MC, Min ES, et al. Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005. Cancer 2009; 115:3526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zucman-Rossi J, Batzer MA, Stoneking M, et al. Interethnic polymorphism of EWS intron 6: genome plasticity mediated by Alu retroposition and recombination. Hum Genet 1997; 99:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Postel-Vinay S, Véron AS, Tirode F, et al. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet 2012; 44:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartley AL, Birch JM, Blair V, et al. Cancer incidence in the families of children with Ewing's tumor. J Natl Cancer Inst 1991; 83:955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buckley JD, Pendergrass TW, Buckley CM, et al. Epidemiology of osteosarcoma and Ewing's sarcoma in childhood: a study of 305 cases by the Children's Cancer Group. Cancer 1998; 83:1440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKeen EA, Hanson MR, Mulvihill JJ, Glaubiger DL. Birth defects with Ewing's sarcoma. N Engl J Med 1983; 309:1522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Novakovic B, Goldstein AM, Wexler LH, Tucker MA. Increased risk of neuroectodermal tumors and stomach cancer in relatives of patients with Ewing's sarcoma family of tumors. J Natl Cancer Inst 1994; 86:1702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang J, Walsh MF, Wu G, et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med 2015; 373:2336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto T, Wakabayashi T. Bone tumors among the atomic bomb survivors of Hiroshima and Nagasaki. Acta Pathol Jpn 1969; 19:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tucker MA, D'Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spunt SL, Rodriguez-Galindo C, Fuller CE, et al. Ewing sarcoma-family tumors that arise after treatment of primary childhood cancer. Cancer 2006; 107:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valery PC, Williams G, Sleigh AC, et al. Parental occupation and Ewing's sarcoma: pooled and meta-analysis. Int J Cancer 2005; 115:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cope JU, Tsokos M, Helman LJ, et al. Inguinal hernia in patients with Ewing sarcoma: a clue to etiology. Med Pediatr Oncol 2000; 34:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holly EA, Aston DA, Ahn DK, Kristiansen JJ. Ewing's bone sarcoma, paternal occupational exposure, and other factors. Am J Epidemiol 1992; 135:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winn DM, Li FP, Robison LL, et al. A case-control study of the etiology of Ewing's sarcoma. Cancer Epidemiol Biomarkers Prev 1992; 1:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valery PC, McWhirter W, Sleigh A, et al. A national case-control study of Ewing's sarcoma family of tumours in Australia. Int J Cancer 2003; 105:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipinski M, Braham K, Philip I, et al. Neuroectoderm-associated antigens on Ewing's sarcoma cell lines. Cancer Res 1987; 47:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKeon C, Thiele CJ, Ross RA, et al. Indistinguishable patterns of protooncogene expression in two distinct but closely related tumors: Ewing's sarcoma and neuroepithelioma. Cancer Res 1988; 48:4307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riggi N, Suvà ML, Suvà D, et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008; 68:2176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torchia EC, Jaishankar S, Baker SJ. Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res 2003; 63:3464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 2000; 18:204.
          </a>
         </li>
         <li class="breakAll">
          Dorfman H, Czerniak B. Bone Tumors, CV Mosby, St. Louis 1997. p.607.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fellinger EJ, Garin-Chesa P, Triche TJ, et al. Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2. Am J Pathol 1991; 139:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weidner N, Tjoe J. Immunohistochemical profile of monoclonal antibody O13: antibody that recognizes glycoprotein p30/32MIC2 and is useful in diagnosing Ewing's sarcoma and peripheral neuroepithelioma. Am J Surg Pathol 1994; 18:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshida A, Sekine S, Tsuta K, et al. NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma. Am J Surg Pathol 2012; 36:993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonescu CR, Owosho AA, Zhang L, et al. Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases. Am J Surg Pathol 2017; 41:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Specht K, Zhang L, Sung YS, et al. Novel BCOR-MAML3 and ZC3H7B-BCOR Gene Fusions in Undifferentiated Small Blue Round Cell Sarcomas. Am J Surg Pathol 2016; 40:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kao YC, Owosho AA, Sung YS, et al. BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas. Am J Surg Pathol 2018; 42:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zucman J, Delattre O, Desmaze C, et al. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes Cancer 1992; 5:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meier VS, Kühne T, Jundt G, Gudat F. Molecular diagnosis of Ewing tumors: improved detection of EWS-FLI-1 and EWS-ERG chimeric transcripts and rapid determination of exon combinations. Diagn Mol Pathol 1998; 7:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagher R, Pham TA, Sorbara L, et al. Molecular confirmation of Ewing sarcoma. J Pediatr Hematol Oncol 2001; 23:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohno T, Ouchida M, Lee L, et al. The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains. Oncogene 1994; 9:3087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burd CG, Dreyfuss G. Conserved structures and diversity of functions of RNA-binding proteins. Science 1994; 265:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hromas R, Klemsz M. The ETS oncogene family in development, proliferation and neoplasia. Int J Hematol 1994; 59:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wasylyk B, Hahn SL, Giovane A. The Ets family of transcription factors. Eur J Biochem 1993; 211:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeon IS, Davis JN, Braun BS, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 1995; 10:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peter M, Couturier J, Pacquement H, et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 1997; 14:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994; 6:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urano F, Umezawa A, Yabe H, et al. Molecular analysis of Ewing's sarcoma: another fusion gene, EWS-E1AF, available for diagnosis. Jpn J Cancer Res 1998; 89:703.
          </a>
         </li>
         <li class="breakAll">
          Ginsberg, JP, Woo, SY, Hicks, MJ, Horowitz, ME. Ewing's sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In: Priniciples and Practice of Pediatric Oncology, 4th ed, Pizzo, PA, Poplack, DG (Eds), Lippincott, Williams and Wilkins, Philadelphia, 2002.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bell RS, Wunder J, Andrulis I. Molecular alterations in bone and soft-tissue sarcoma. Can J Surg 1999; 42:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obata K, Hiraga H, Nojima T, et al. Molecular characterization of the genomic breakpoint junction in a t(11;22) translocation in Ewing sarcoma. Genes Chromosomes Cancer 1999; 25:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng TL, O'Sullivan MJ, Pallen CJ, et al. Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. J Mol Diagn 2007; 9:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shing DC, McMullan DJ, Roberts P, et al. FUS/ERG gene fusions in Ewing's tumors. Cancer Res 2003; 63:4568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zucman J, Delattre O, Desmaze C, et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet 1993; 4:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panagopoulos I, Höglund M, Mertens F, et al. Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene 1996; 12:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabbitts TH, Forster A, Larson R, Nathan P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 1993; 4:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hattinger CM, Rumpler S, Strehl S, et al. Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. Genes Chromosomes Cancer 1999; 24:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armengol G, Tarkkanen M, Virolainen M, et al. Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br J Cancer 1997; 75:1403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savola S, Klami A, Tripathi A, et al. Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer 2009; 9:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovar H, Auinger A, Jug G, et al. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 1993; 8:2683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovar H, Jug G, Aryee DN, et al. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 1997; 15:2225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang HY, Illei PB, Zhao Z, et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 2005; 23:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tirode F, Surdez D, Ma X, et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov 2014; 4:1342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crompton BD, Stewart C, Taylor-Weiner A, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov 2014; 4:1326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brohl AS, Solomon DA, Chang W, et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet 2014; 10:e1004475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon DA, Kim T, Diaz-Martinez LA, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 2011; 333:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lerman DM, Monument MJ, McIlvaine E, et al. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2015; 62:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           May WA, Lessnick SL, Braun BS, et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993; 13:7393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrero-Martín D, Osuna D, Ordóñez JL, et al. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. Br J Cancer 2009; 101:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tirado OM, Mateo-Lozano S, Villar J, et al. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res 2006; 66:9937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 2001; 20:5747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohno T, Rao VN, Reddy ES. EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res 1993; 53:5859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bailly RA, Bosselut R, Zucman J, et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 1994; 14:3230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kinsey M, Smith R, Iyer AK, et al. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma. Cancer Res 2009; 69:9047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorthi A, Romero JC, Loranc E, et al. EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature 2018; 555:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           May WA, Gishizky ML, Lessnick SL, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A 1993; 90:5752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toretsky JA, Kalebic T, Blakesley V, et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997; 272:30822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toretsky JA, Steinberg SM, Thakar M, et al. Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer 2001; 92:2941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008; 7:2575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakatani F, Tanaka K, Sakimura R, et al. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem 2003; 278:15105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka K, Iwakuma T, Harimaya K, et al. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997; 99:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toretsky JA, Connell Y, Neckers L, Bhat NK. Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol 1997; 31:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res 2006; 4:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004; 24:7275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith R, Owen LA, Trem DJ, et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 2006; 9:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erkizan HV, Kong Y, Merchant M, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 2009; 15:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovar H, Aryee DN, Jug G, et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 1996; 7:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hancock JD, Lessnick SL. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 2008; 7:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kauer M, Ban J, Kofler R, et al. A molecular function map of Ewing's sarcoma. PLoS One 2009; 4:e5415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo W, Gangwal K, Sankar S, et al. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Oncogene 2009; 28:4126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS One 2008; 3:e1965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yi H, Fujimura Y, Ouchida M, et al. Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias. Oncogene 1997; 14:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takahashi A, Higashino F, Aoyagi M, et al. EWS/ETS fusions activate telomerase in Ewing's tumors. Cancer Res 2003; 63:8338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Italiano A, Di Mauro I, Rapp J, et al. Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study. Lancet Oncol 2016; 17:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diffin F, Porter H, Mott MG, et al. Rapid and specific diagnosis of t(11;22) translocation in paediatric Ewing's sarcoma and primitive neuroectodermal tumours using RNA-PCR. J Clin Pathol 1994; 47:562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Downing JR, Head DR, Parham DM, et al. Detection of the (11;22)(q24;q12) translocation of Ewing's sarcoma and peripheral neuroectodermal tumor by reverse transcription polymerase chain reaction. Am J Pathol 1993; 143:1294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor C, Patel K, Jones T, et al. Diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumour based on the detection of t(11;22) using fluorescence in situ hybridisation. Br J Cancer 1993; 67:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ladanyi M. The emerging molecular genetics of sarcoma translocations. Diagn Mol Pathol 1995; 4:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Alava E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998; 16:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996; 14:1245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Doorninck JA, Ji L, Schaub B, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2010; 28:1989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Deley MC, Delattre O, Schaefer KL, et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol 2010; 28:1982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Athale UH, Shurtleff SA, Jenkins JJ, et al. Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewing sarcoma family of tumors, and desmoplastic small round cell tumor. J Pediatr Hematol Oncol 2001; 23:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           West DC, Grier HE, Swallow MM, et al. Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor. J Clin Oncol 1997; 15:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Alava E, Lozano MD, Patiño A, et al. Ewing family tumors: potential prognostic value of reverse-transcriptase polymerase chain reaction detection of minimal residual disease in peripheral blood samples. Diagn Mol Pathol 1998; 7:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zoubek A, Ladenstein R, Windhager R, et al. Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: a preliminary evaluation. Int J Cancer 1998; 79:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fagnou C, Michon J, Peter M, et al. Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor. Société Française d'Oncologie Pédiatrique. J Clin Oncol 1998; 16:1707.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7742 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9286296" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6083729" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The neuroectodermal tumor of bone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1203852" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Extraskeletal neoplasm resembling Ewing's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35443099" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Ewing sarcoma and related FET family translocation-associated round cell tumors: A century of clinical and scientific progress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/222426" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3113717" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Small round blue cell sarcoma of bone mimicking atypical Ewing's sarcoma with neuroectodermal features. An analysis of five cases with immunohistochemical and electron microscopic support.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1848471" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8022439" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8597892" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Gene rearrangements in Ewing's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1701108" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Soft tissue Ewing's sarcoma. Characterization in established cultures and xenografts with evidence of a neuroectodermic phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1786632" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Biology of pediatric peripheral neuroectodermal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7798952" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A Ewing's sarcoma cell line showing some, but not all, of the traits of a cholinergic neuron.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9622091" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The Ewing tumor family of peripheral primitive neuroectodermal tumors expresses human gastrin-releasing peptide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17482132" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Mesenchymal stem cell features of Ewing tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17482132" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Mesenchymal stem cell features of Ewing tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16919776" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16919776" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12439716" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Classification and incidence of cancers in adolescents and young adults in England 1979-1997.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12439716" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Classification and incidence of cancers in adolescents and young adults in England 1979-1997.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11515030" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Epidemiology of bone cancer in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7029300" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Contrasting epidemiology of childhood osteosarcoma, Ewing's tumor, and rhabdomyosarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4189632" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Rarity of Ewing's sarcoma among U.S. Negro children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8428791" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : International variations in the incidence of childhood bone tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19548262" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9050923" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Interethnic polymorphism of EWS intron 6: genome plasticity mediated by Alu retroposition and recombination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22327514" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2067039" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Cancer incidence in the families of children with Ewing's tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9762947" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Epidemiology of osteosarcoma and Ewing's sarcoma in childhood: a study of 305 cases by the Children's Cancer Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6646179" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Birth defects with Ewing's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7966398" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Increased risk of neuroectodermal tumors and stomach cancer in relatives of patients with Ewing's sarcoma family of tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26580448" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Germline Mutations in Predisposition Genes in Pediatric Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4900394" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Bone tumors among the atomic bomb survivors of Hiroshima and Nagasaki.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3475572" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Bone sarcomas linked to radiotherapy and chemotherapy in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16721801" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Ewing sarcoma-family tumors that arise after treatment of primary childhood cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15704156" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Parental occupation and Ewing's sarcoma: pooled and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10696126" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Inguinal hernia in patients with Ewing sarcoma: a clue to etiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1311140" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Ewing's bone sarcoma, paternal occupational exposure, and other factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1302564" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A case-control study of the etiology of Ewing's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12767069" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A national case-control study of Ewing's sarcoma family of tumours in Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3024814" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Neuroectoderm-associated antigens on Ewing's sarcoma cell lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3390826" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Indistinguishable patterns of protooncogene expression in two distinct but closely related tumors: Ewing's sarcoma and neuroepithelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18381423" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12839926" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10623711" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10623711" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1867320" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7513503" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Immunohistochemical profile of monoclonal antibody O13: antibody that recognizes glycoprotein p30/32MIC2 and is useful in diagnosing Ewing's sarcoma and peripheral neuroepithelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22446943" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28346326" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26752546" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Novel BCOR-MAML3 and ZC3H7B-BCOR Gene Fusions in Undifferentiated Small Blue Round Cell Sarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29300189" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1522903" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1283315" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9646032" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Molecular diagnosis of Ewing tumors: improved detection of EWS-FLI-1 and EWS-ERG chimeric transcripts and rapid determination of exon combinations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11846300" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Molecular confirmation of Ewing sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8084618" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8036511" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Conserved structures and diversity of functions of RNA-binding proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8086619" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The ETS oncogene family in development, proliferation and neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8425553" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The Ets family of transcription factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7700648" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9121764" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : A new member of the ETS family fused to EWS in Ewing tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8162068" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9738976" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Molecular analysis of Ewing's sarcoma: another fusion gene, EWS-E1AF, available for diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9738976" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Molecular analysis of Ewing's sarcoma: another fusion gene, EWS-E1AF, available for diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10459325" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Molecular alterations in bone and soft-tissue sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10221334" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Molecular characterization of the genomic breakpoint junction in a t(11;22) translocation in Ewing sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17620387" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12907633" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : FUS/ERG gene fusions in Ewing's tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8401579" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8637704" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Fusion of the EWS and CHOP genes in myxoid liposarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7503811" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10451705" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9166930" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19144156" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8378080" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9393981" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15659501" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25223734" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25186949" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The genomic landscape of pediatric Ewing sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25010205" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21852505" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Mutational inactivation of STAG2 causes aneuploidy in human cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25464386" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8246959" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19491900" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17047056" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11607824" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Biology of EWS/ETS fusions in Ewing's family tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7503813" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : EWS/Fli-1 chimeric protein is a transcriptional activator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8164678" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19920188" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29513652" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8516324" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9388225" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11753970" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18790742" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12560328" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9005992" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9049825" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17114343" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15282325" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16697960" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19584866" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9052984" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18256529" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19404404" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : A molecular function map of Ewing's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19718047" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18414662" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9178886" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14678994" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : EWS/ETS fusions activate telomerase in Ewing's tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26970672" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8063945" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Rapid and specific diagnosis of t(11;22) translocation in paediatric Ewing's sarcoma and primitive neuroectodermal tumours using RNA-PCR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8238248" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Detection of the (11;22)(q24;q12) translocation of Ewing's sarcoma and peripheral neuroectodermal tumor by reverse transcription polymerase chain reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8381297" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumour based on the detection of t(11;22) using fluorescence in situ hybridisation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7493135" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : The emerging molecular genetics of sarcoma translocations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9552022" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8648380" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20308669" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20308673" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11216714" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewing sarcoma family of tumors, and desmoplastic small round cell tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9053480" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9836070" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Ewing family tumors: potential prognostic value of reverse-transcriptase polymerase chain reaction detection of minimal residual disease in peripheral blood samples.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9495359" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: a preliminary evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9586882" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor. SociétéFrançaise d'Oncologie Pédiatrique.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
